Researchers continue to group MK-677 and CJC-1295 because the surface-level story is the same: both raise growth hormone, both increase IGF-1, and both appear in body composition studies. The grouping makes sense until you look at how each one actually works. MK-677 for sale is an oral ghrelin mimic. CJC-1295 is an injected GHRH analog. They bind to completely different receptors, run through distinct signaling pathways, and produce distinct side-effect profiles. The fact that both move the same lab marker is almost misleading.
That receptor gap is where protocol decisions live. A finding from MK-677 research does not necessarily transfer to CJC-1295, even when the IGF-1 levels appear comparable. Think of two antihypertensives that both lower blood pressure, one blocks calcium channels, and the other inhibits ACE. You would not run a trial on one and assume the results apply to the other. The same logic applies here. Both compounds are available through Purerawz alongside a broader catalog of SARMs and research peptides. Understanding where they split is the work that comes before sourcing either one.
What MK-677 and CJC-1295 Are Actually Targeting
Your body runs GH release through two competing signals at all times. GHRH travels from the hypothalamus to the pituitary and signals the release of GH. Somatostatin travels the same route and says, ‘Don’t.’ Ghrelin throws a wrench in by hitting both the brain and the pituitary, pushing the gas harder while taking pressure off the brakes. The GH burst that follows is larger than GHRH could pull off alone. That is the mechanism MK-677 copies.
Here is what most comparisons skip: GH does not trickle out steadily. It fires in sharp bursts, mostly while you sleep. Those bursts are what push the liver to make IGF-1, keep your tissues from becoming desensitized to the signal, and prevent the whole system from downregulating itself over time. Flatten those pulses into a slow drip, and you lose more than peak output. The downstream effects stop working the way they should.
MK-677 and CJC-1295 both operate inside this system, but enter at different doors. MK-677 mimics ghrelin, binding to GHS-R1a and boosting GH output while pulling back on somatostatin’s brake. CJC-1295 mimics GHRH, binds GHRHR, and boosts the signal, while somatostatin runs in the background, completely untouched. A blood test can show identical IGF-1 numbers for both. That tells you almost nothing about what is actually different between them.
MK-677 (Ibutamoren): Mechanism and Evidence
How It Works
When you take MK-677 orally, it binds to ghrelin receptors in both the brain and the pituitary gland. Once it locks in, it triggers a chain reaction in the cell that culminates in the pituitary releasing a pulse of growth hormone. That is the direct stimulation side of things.
At the same time, MK-677 also dials back somatostatin, which is the signal that normally tells your body to hold off on releasing GH. So it is pushing on the gas and easing off the brake at the same time. That is why MK-677 tends to produce bigger GH increases than GHRH-based compounds like CJC-1295.
A few things that make MK-677 stand out from everything else in this category:
- It is taken as a pill. Every other GH secretagogue with real human research behind it requires an injection. That matters in protocols where injecting is not practical.
- It has a long half-life of around 24 hours. Ghrelin receptors stay occupied throughout the day, keeping GH levels modestly elevated around the clock.
- It still allows natural GH pulses. Larger bursts continue firing during deep sleep on top of the steady baseline elevation.
Clinical Evidence
MK-677 has more published human trial data behind it than any other unapproved GH secretagogue. Three studies make up the core of that evidence:
- Chapman et al. (1996) administered 25 mg daily to healthy elderly subjects. 24-hour GH secretion rose 60 to 97 percent above baseline.
- Svensson et al. (1998) ran subjects on 25 mg per day for twelve months. Average IGF-1 climbed from 128 ng/mL to 242 ng/mL, an 89 percent increase that held steady through the end of the study without fading.
- Nass et al. (2008) is the most rigorous trial in the literature. Two years, double-masked, placebo-controlled, in adults aged 60 to 81. Key findings included:
- GH and IGF-1 stayed at levels typical of younger adults throughout
- Lean mass came in 1.1 kg higher than placebo
- Fasting glucose rose by around 5.4 mg/dL
- Insulin sensitivity declined noticeably
- No receptor downregulation after two full years of daily use
That last point is worth paying attention to. Two years of daily use with no receptor downregulation is not something you see often in this class.
Side Effects to Monitor
Ghrelin receptors are not only in the brain and pituitary gland. They also sit in the gut, pancreas, heart, and central nervous system. MK-677 activates them wherever they are. Here is what to watch for:
- Increased appetite. This is built into the mechanism, not a random side effect. Activating ghrelin receptors in the hypothalamus triggers hunger. Most users find it fades noticeably after the first few months.
- Insulin resistance and elevated fasting glucose. This is the main metabolic concern. GH on its own already reduces insulin sensitivity, and MK-677 adds to that effect. Anyone with existing blood sugar issues needs to factor this in before starting.
- Water retention. GH promotes fluid and sodium retention through the kidneys. Mild swelling in the lower legs and ankles is the most common presentation.
- Sleep changes. REM sleep increases by roughly 50 percent, and slow-wave deep sleep by around 20 percent, consistent with GH’s effects on sleep stages overall.
CJC-1295: Mechanism and Evidence
How It Works
Your body makes its own version of GHRH, but it has a problem. It breaks down in the bloodstream within about 7 minutes. By the time a natural GHRH injection reaches the pituitary, most of it is already ineffective. That is why nobody ever built a working therapy around it. CJC-1295 was built to solve that exact problem. Same signal, stays active much longer. One thing that does not change, regardless of which version you use, is that it always requires an injection. There is no pill version.
Two Versions, Two Very Different Protocols
This is the part that trips people up most often. The two versions of CJC-1295 share a name but behave differently enough that treating them as interchangeable will break your protocol:
- CJC-1295 with DAC. The DAC modification causes the peptide to latch onto albumin, a protein already circulating in your blood, which protects it from breaking down. Half-life goes from about 30 minutes to close to a week. One or two injections per week get the job done.
- CJC-1295 without DAC (Modified GRF 1-29). Same core peptide, no albumin binding. Half-life drops back to around 30 minutes, so you need two to three injections per day. The tradeoff is that the GH release pattern stays much closer to what your body does naturally.
What Happens at the Receptor Level
Once CJC-1295 reaches the pituitary, it binds to GHRH receptors, triggering a chain of events that culminates in GH release. Three things worth knowing about how that plays out:
- Somatostatin never gets touched. CJC-1295 only works the gas pedal. The brake stays on the whole time.
- GH release stays pulsatile. Because somatostatin is still running, the body keeps firing GH in natural bursts rather than a steady drip.
- That makes it the closest match to natural physiology compared to compounds that suppress somatostatin at the same time.
That last point has real implications for long-term receptor sensitivity and how consistently the downstream IGF-1 response holds up over time.
What the Research Shows
One published human trial on CJC-1295 is Teichman et al. (2006), which included 65 healthy adults aged 21 to 61. Here is what the data showed:
- Single injection: GH climbed 2 to 10 times above baseline and stayed there for at least 6 days. IGF-1 followed, rising 1.5 to 3 times above normal and holding for 9 to 11 days.
- Repeated dosing: IGF-1 kept building. With continued injections, levels stayed elevated for up to 28 days.
- Half-life: 5.8-8.1 days for the DAC version. One or two injections per week are enough to maintain elevation.
- Side effects: None serious at the tested doses. Injection site reactions, occasional flushing, and some water retention at higher doses.
Why the Evidence Stops Here
ConjuChem walked away before Phase III, a business decision, not a safety signal.
What that leaves researchers with:
- Short-term safety data from Phase I and II look fine
- No long-term body composition or outcomes study exists
- MK-677 has a two-year RCT behind it; CJC-1295 does not. If you are comparing the two, that gap is not a minor footnote.
Head-to-Head Comparison
| Parameter | MK-677 | CJC-1295 |
| Receptor target | Ghrelin receptor (GHS-R1a) | GHRH receptor (GHRHR) |
| Administration | Oral | Subcutaneous injection |
| Half-life | ~24 hours | 5.8-8.1 days (DAC); ~30 min (no DAC) |
| GH release pattern | Steady baseline + larger sleep pulses | Natural pulsatile rhythm preserved |
| Appetite stimulation | Yes, built into the mechanism | No |
| Insulin resistance | Documented in trials | Not documented |
| Longest human trial | 2 years (Nass et al., 2008) | Phase I/II only (Teichman et al., 2006) |
| Body composition data | Yes (+1.1 kg lean mass) | None published |
| FDA approval | No | No |
Combining MK-677 and CJC-1295
These two compounds get paired in protocols because they do not compete for the same receptor. CJC-1295 primes the pituitary through the GHRH receptor. MK-677 pulls the trigger through the ghrelin receptor while simultaneously reducing somatostatin’s braking effect. The resulting GH pulse is larger than either compound produces when working alone.
Published data on CJC-1295 paired with ipamorelin, another ghrelin receptor agonist, already demonstrate that combining stimulation of the GHRH and ghrelin pathways outperforms either compound alone. The same receptor logic applies to CJC-1295 plus MK-677. What is still missing is a direct peer-reviewed human trial on that specific pairing. Biomarker monitoring throughout is not optional for any combination protocol.
One clarification before building a stack: doubling up on ghrelin receptor compounds does not work the same way. Pairing MK-677 with ipamorelin or GHRP-6 puts two agonists on the same receptor. That does not amplify output the way hitting complementary receptor systems does. Synergy requires different nodes in the pathway.
Choosing the Right Compound
Neither compound is universally better. The right choice comes down to what your protocol actually needs. Here is a plain breakdown:+
Choose MK-677 when:
- You need something taken by mouth, no injections
- Appetite, cortisol, or sleep quality are things you are actively tracking or trying to improve
- You want the compound with the longest human trial record in this class
- Sustained IGF-1 elevation over several months without the response fading is your main goal
Choose CJC-1295 when:
- You need GH to release in natural pulses rather than a steady baseline. The no-DAC version is the right fit here.
- Your protocol involves people with existing blood sugar issues or metabolic risk factors that make MK-677’s effect on insulin sensitivity a real concern
- Injection frequency matters practically; the DAC version only needs to be taken once a week
- You need to remove hunger-related effects as a variable in your design
Biomarkers to Track Regardless of Which You Use
Do not skip these. They apply to both compounds, though some are more critical with MK-677:
- Fasting glucose and HbA1c. Non-negotiable with MK-677. Strongly advisable with CJC-1295. This is the first thing that will show a problem if something is going wrong metabolically.
- Serum IGF-1. Track this throughout. If it consistently reads above 400 ng/mL, review your dose.
- Lipid panel and blood pressure. Both can shift with sustained GH elevation. Worth checking at baseline and periodically through the protocol.
- Baseline pituitary MRI. Get this before starting either compound. You need to rule out an existing adenoma before introducing anything that stimulates the pituitary.
Regulatory Status
Neither compound is FDA-approved. MK-677 is on the WADA prohibited list and classified as a research compound in most jurisdictions. Merck investigated it for GH deficiency, muscle wasting, and hip fracture recovery, but discontinued development before approval, citing concerns about insulin sensitivity as a factor in the benefit-risk calculus. CJC-1295 has no approved clinical application in any major regulatory territory. Enforcement scrutiny is increasing globally, with compounding pharmacies and research peptide suppliers feeling it most directly. The rules vary by jurisdiction, and they change. Researchers need to track what applies where they operate, not where the compound ships from.
Conclusion
These are not interchangeable compounds. Same endpoint on a blood test, completely different receptors, different mechanisms, different side effect profiles, and significantly different amounts of human evidence behind them. Protocols that treat them as equivalent are not just suboptimal; they are building on a category error.
MK-677’s case rests on two things no other compound in the class can claim: oral delivery and a two-year randomized controlled trial. The tradeoffs are real and documented. Appetite stimulation, insulin resistance, and glucose changes come with the ghrelin receptor mechanism and require active monitoring throughout any protocol.
CJC-1295 has a cleaner metabolic side-effect profile. No hunger pathway activation, no documented insulin resistance, GH pulses preserved, and once-weekly dosing with the DAC version. What it lacks is a long-term outcomes trial. The pharmacokinetics are well-characterized. The body composition question has not yet been answered.
Used together, the scientific rationale holds that different receptors, complementary pathways, and a stronger combined output. What is absent is a peer-reviewed human trial testing that pairs directly. Build combination protocols with that gap in mind.
Purity is non-negotiable with either compound. Impure or mislabeled material invalidates the protocol regardless of how well it was designed. Third-party CoA documentation is the minimum bar. Purerawz publishes that documentation for its research compounds, making it a practical starting point for researchers who need verified material before any protocol begins.
References
- Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)–insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249–4257. doi:10.1210/jcem.81.12.8954023
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. doi:10.1210/jc.2005-1536
- Fernández-Garza LE, Guillén-Silva F, Sotelo-Ibarra MA, et al. Growth hormone and aging: a clinical review. Front Aging. 2025;6:1549453. doi:10.3389/fragi.2025.1549453
- Smith RG, Thorner MO. Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects to that observed in young adults. J Gerontol A Biol Sci Med Sci. 2023;78(Suppl 1):38–43. doi:10.1093/gerona/glad022
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601–611. doi:10.7326/0003-4819-149-9-200811040-00003
